Inventiva (NASDAQ:IVA) Research Coverage Started at Barclays

Barclays initiated coverage on shares of Inventiva (NASDAQ:IVA) in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports. The firm issued an overweight rating and a $18.00 target price on the stock.

IVA has been the topic of several other research reports. Leerink Partners began coverage on Inventiva in a research report on Monday, January 12th. They set an “outperform” rating and a $12.00 target price on the stock. Guggenheim dropped their price objective on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 target price on shares of Inventiva in a research note on Tuesday, September 30th. Wolfe Research upgraded shares of Inventiva to a “strong-buy” rating in a report on Thursday, November 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $16.22.

Inventiva Trading Down 7.5%

IVA opened at $6.32 on Tuesday. The stock has a 50-day moving average of $5.01 and a 200 day moving average of $4.78. Inventiva has a 12 month low of $2.23 and a 12 month high of $7.98.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Creative Planning bought a new stake in Inventiva during the 2nd quarter valued at about $32,000. Wealth Enhancement Advisory Services LLC increased its position in shares of Inventiva by 54.5% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after acquiring an additional 5,843 shares during the period. NewEdge Advisors LLC bought a new stake in shares of Inventiva during the third quarter valued at approximately $116,000. Millennium Management LLC purchased a new stake in shares of Inventiva in the third quarter valued at approximately $649,000. Finally, UBS Group AG grew its stake in Inventiva by 28,881.6% in the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after purchasing an additional 2,634,580 shares in the last quarter. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.